Patent ID: 6221860
Filing Date: 2001-04-24
Classification: A61K

Abstract:
A method for treating disease or disorders mediated by a lipid inflammatory mediator selected from arachidonric acid, its metabolites or platelet activating factor (PAF), which method comprising administering to a mammal in need thereof an effective Coenzyme A independent transacylase (CoA-IT) inhibiting amount of a compound of the Formula: ##STR5##whereinY is NH;X is O or S(O)m;m is 0 or an integer having a value of 1, or 2;R.sub.3 is optionally substituted triphenylmethyl;R.sub.4 is optionally substituted C.sub.1-10 alkyl, (CR.sub.10 R.sub.20).sub.n C(R.sub.10)=C(R.sub.7).sub.2, or (CR.sub.10 R.sub.20)n--C.tbd.C--R.sub.5 ;n is an integer having a value of 1 to 4;R.sub.10 and R.sub.20 are independently hydrogen or C.sub.1-4 alkyl;R.sub.5 is hydrogen, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C(O).sub.2 R.sub.6, or C(O)R.sub.6 wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl moieties may be optionally substituted;R.sub.6 is C.sub.1-10 alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclic, or heterocyclicalkyl, wherein the alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclic, or heterocyclicalkyl moieties may be optionally substituted;R.sub.7 is independently hydrogen, C.sub.1-10 alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclic, or heterocyclicalkyl, wherein the alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclic, or heterocyclicalkyl moieties may be optionally substituted;or a pharmaceutically acceptable salt thereof.